BKC,

Thanks for posting that link to the article titled "BRD4 is a novel therapeutic target for liver fibrosis." That definitely exemplified the potential for BET inhibition to alleviate liver fibrosis.

There was another recent article that came out entitled "BRD4 regulates fructose-inducible lipid accumulation-related genes in the mouse liver." High-carbohyrate diets (especially those derived from sugars and ESPECIALLY those high in fructose) promote increased fatty acid synthesis gene expression in the liver and lead to accumulation of lipids in the liver by way of conversion of carbohydrates into fatty acids. Over time, this chronic hepatic fat accumulation, aka hepatic steatosis, can progress to non-alcoholic steatohepatitis (NASH). So that is great news if ANOTHER metabolic effect of BET inhibition is to alleviate fatty liver.

Caveat, the above studies were done with the pan BET inhibitor JQ1 and not a BD2-selective inhibitor like RVX-208.

BearDownAZ